SCHEMBL12293177

SCHEMBL12293177

CCNc1ccc(C(C)(C)C)cn1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCAR3 P49019 3/20 0.50
ADRA2A P08913 2/20 0.47
ADRA2B P18089 2/20 0.47
ADRA2C P18825 2/20 0.47
RAB9A P51151 4/20 0.46
MAPT P10636 3/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
GAA P10253 2/20 0.46
LMNA P02545 2/20 0.46
MEN1 O00255 1/20 0.46
HTT P42858 1/20 0.46
KMT2A Q03164 1/20 0.46
DEGS1 O15121 1/20 0.41
NPC1 O15118 3/20 0.40
PIK3CD O00329 1/20 0.38
PIP5K1C O60331 1/20 0.38
PIK3CA P42336 1/20 0.38
PIK3CB P42338 1/20 0.38
PI4KA P42356 1/20 0.38
PIK3CG P48736 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21017113 0.85 HCAR3 (0.51) HCAR3ADRA2AADRA2BADRA2CRAB9A
SCHEMBL12293195 0.85 HCAR3 (0.53) HCAR3RAB9AMAPTSMN1; SMN2GAA
SCHEMBL26199978 0.84 RAB9A (0.43) HCAR3ADRA2AADRA2BADRA2CRAB9A
SCHEMBL4219951 0.83 RAB9A (0.56) HCAR3ADRA2AADRA2BADRA2CRAB9A
SCHEMBL24124013 0.80 RAB9A (0.43) HCAR3RAB9AMAPTSMN1; SMN2GAA
SCHEMBL13658049 0.80 RAB9A (0.43) HCAR3RAB9AMAPTSMN1; SMN2GAA
SCHEMBL12412536 0.80 HCAR3 (0.54) HCAR3RAB9AMAPTSMN1; SMN2GAA
SCHEMBL17403570 0.80 RAB9A (0.46) HCAR3ADRA2AADRA2BADRA2CRAB9A
SCHEMBL14349627 0.80 RAB9A (0.43) HCAR3RAB9AMAPTSMN1; SMN2GAA
SCHEMBL17342209 0.80 RAB9A (0.43) HCAR3ADRA2AADRA2BADRA2CRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230382909-A1 BICYCLIC COMPOUNDS ALIGOS THERAPEUTICS, INC. 2023-11-30 US disclosed
US-20230374008-A1 BICYCLIC COMPOUNDS ALIGOS THERAPEUTICS, INC. 2023-11-23 US disclosed
US-20110224231-A1 Novel Lactams as Beta Secretase Inhibitors PFIZER INC. (US) 2011-09-15 US disclosed
US-20110224231-A1 Novel Lactams as Beta Secretase Inhibitors PFIZER INC. (US) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230382909-A1 BICYCLIC COMPOUNDS SLC10A1, PKD1, CYP11B2 HCAR3 2892/4885ADRA2A 1137/4885ADRA2B 1404/4885
US-20230374008-A1 BICYCLIC COMPOUNDS SLC10A1, PKD1, CYP11B2 HCAR3 2892/4885ADRA2A 1137/4885ADRA2B 1404/4885
US-20110224231-A1 Novel Lactams as Beta Secretase Inhibitors BACE1, BACE2, APH1B HCAR3 4358/4885ADRA2A 2209/4885ADRA2B 1147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.